Decibel Therapeutics

69 articles with Decibel Therapeutics

• Decibel Therapeutics to Present at the H.C. Wainwright Global Investment Conference

  5/17/2022

  Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference.

• Decibel Therapeutics Reports First Quarter 2022 Financial Results and Corporate Update

  5/12/2022

  Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.

• Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting

  5/2/2022

  Decibel Therapeutics announced today that it will present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, being held virtually and in Washington D.C. May 15-19, 2022.

• Decibel Therapeutics to Participate in Upcoming Investor Conferences - Mar 22, 2022

  3/22/2022

  Decibel Therapeutics announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in the following upcoming virtual investor conferences in March.

• Decibel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

  3/18/2022

  Decibel Therapeutics today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.

• Decibel Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

  2/10/2022

  Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference,

• Decibel Therapeutics Reports on Continued Progress of Lead Gene Therapy Product Candidate DB-OTO and Presents Promising Preclinical Data Supporting Importance of Cell-Selective Transgene Expression Across Gene Therapy Pipeline

  2/9/2022

  Decibel Therapeutics (Nasdaq: DBTX), announced the presentation of preclinical data on its lead gene therapy product candidate, DB-OTO.

• Decibel Therapeutics to Present at the 45th Annual Association for Research in Otolaryngology (ARO) Meeting

  1/31/2022

  Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced today that it will present findings from its drug discovery and development programs at the 45th Annual MidWinter Meeting of the Association for Research in Otolaryngology (ARO).

• Decibel Therapeutics to Present at the H.C. Wainwright BioConnect Conference

  1/4/2022

  Decibel Therapeutics announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in a fireside chat at the H.C. Wainwright BioConnect Conference.

• Decibel Therapeutics Announces Appointments of Alison Finger, MBA and Saraswathy Nochur, Ph.D. to its Board of Directors; Christine Poon Steps Down from Board

  12/6/2021

  Decibel Therapeutics today announced the appointments of Alison Finger, MBA and Saraswathy (“Sara”) Nochur, Ph.D. to its Board of Directors.

• Decibel Therapeutics Announces Extension of Research Term under Strategic Collaboration with Regeneron to Discover and Develop Gene Therapies for Hearing Loss

  11/22/2021

  Decibel Therapeutics today announced that Regeneron has extended the research term of its collaboration with the Company to discover and develop gene therapies for hearing loss.

• Decibel Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update

  11/10/2021

  Decibel Therapeutics today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

• Decibel Therapeutics to Present at the Barclays Gene Editing & Gene Therapy Summit

  11/8/2021

  Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced its participation in the fifth annual Barclays Gene Editing & Gene Therapy Summit on Monday, November 15, 2021.

• Decibel Therapeutics to Present at the Jefferies Gene Therapy/Editing Summit

  10/20/2021

  Decibel Therapeutics today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in a fireside chat at the Jefferies Gene Therapy/Editing Summit on Wednesday, October 27, 2021 at 10:30 am ET.

• Decibel Therapeutics Announces Publication of Foundational Study of Noise-related Inner Ear Damage

  9/30/2021

  Decibel Therapeutics (Nasdaq: DBTX), today announced that findings from a study of noise-related inner ear damage conducted in collaboration with the University of Maryland School of Medicine (UMSOM) and the Karolinska Institute (KI) have been published in Cell Reports.

• Decibel Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations for DB-OTO for the Treatment of Otoferlin-Related Congenital Hearing Loss

  9/9/2021

  Decibel Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug Designation and Rare Pediatric Disease Designation for the company’s lead gene therapy product candidate, DB-OTO, for the treatment of patients with otoferlin-related congenital hearing loss.

• Decibel Therapeutics to Present at Upcoming Investor Conferences - Sep 02, 2021

  9/2/2021

  Decibel Therapeutics, a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced that the Company will participate in the following upcoming virtual investor conferences in September.

• Decibel Therapeutics Appoints Cynthia Hu as Chief Legal Officer and Corporate Secretary

  8/18/2021

  Decibel Therapeutics today announced the appointment of Cynthia Hu, J.D., as Chief Legal Officer and Corporate Secretary.

• Decibel Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update

  8/10/2021

  Decibel Therapeutics today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.

• Decibel Therapeutics Appoints Dr. William H. Carson as Chairman of the Board of DirectorsDistinguished biopharma executive brings over 20 years of leadership in life sciences

  6/2/2021

  Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of William (Bill) H. Carson, M.D., as Chairman of the Board of Directors.